The approval marks the first for a targeted treatment in chronic spontaneous urticaria in Europe in over a decad ...

Interestingly, despite the autumn’s upward trend, November’s haul is the first in 2025 that doesn’t outweigh the ...

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are ...

Citi Annual Global Healthcare Conference 2025 December 3, 2025 9:45 AM ESTCompany ParticipantsJane Pritchett Henderson ...

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years ...

Regeneron Pharmaceuticals, Inc. ( REGN) Evercore 8th Annual Healthcare Conference December 2, 2025 1:20 PM EST ...

According to DataM Intelligence. The Prescription Drugs Market Size, valued at a substantial US$1240.33 billion in 2024, is projected to ...

Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria ...

Canaccord raised the firm’s price target on Regeneron (REGN) to $1,057 from $850 and keeps a Buy rating on the shares. The firm said they expect ...

Regeneron (REGN) and Sanofi (SNY) announced that the European Commission has approved Dupixent for the treatment of moderate-to-severe chronic ...

Regeneron Pharmaceuticals and Sanofi have won European Commission expanded approval of their blockbuster anti-inflammatory drug Dupixent for certain patients with the inflammatory skin condition ...

The European Commission has approved Sanofi and Regeneron’s Dupixent for the treatment of moderate-to-severe chronic spontaneous urticaria.